Thrombocytopenia is a hallmark for patients with cirrhosis and it is perceived as a risk factor for bleeding events. However, the relationship between platelet count and bleeding is still unclear.
INTRODUCTION
Cirrhosis is associated with laboratory variable changes indicating the presence of a coagulopathy that could theoretically predispose to bleeding. Th us, global clotting tests, such as prothrombin time and activated partial thromboplastin time, are prolonged as a consequence of impaired clotting factor synthesis by liver failure ( 1 ) . Th e clinical relevance of this fi nding has been long questioned as such changes do not refl ect in vivo clotting activation that is, in fact, increased more than decreased in cirrhosis (2) (3) (4) . In particular, we reported an enhanced rate of thrombin generation in cirrhotic patients depending on the degree of liver failure that was more marked in portal compared with systemic circulation ( 5 ) . Th is fi nding leads to suggest that endotoxemia from gut microbiota could exert a procoagulant eff ect via upregulation of Tissue Factor, a glycoprotein that converts factor X to Xa ( 6 ) . In accordance with this hypothesis, administration of nonabsorbable antibiotic resulted in coincident lowering of endotoxemia and thrombin generation ( 7 ) . Th e paradoxical coexistence of enhanced thrombin generation with activated partial thromboplastin time prolongation may be dependent on the fact that clotting tests lack sensitivity to the concomitant downregulation of anticoagulants that are also poorly synthetized in case of liver Platelet Count Does Not Predict Bleeding in Cirrhotic Patients: Results from the PRO-LIVER Study failure ( 8 ) . In accordance with this, there is no correlation between bleeding risk and clotting tests such as prothrombin time and activated partial thromboplastin time in cirrhosis ( 2, 3 ) .
Platelet dysfunction is another putative component of coagulopathy that has been suggested as contributing to bleeding. Th e presence of coagulopathy in cirrhosis has been based on ex vivo studies demonstrating impaired platelet response to common agonists ( 9 ) . However, the existence of platelet dysfunction has been recently questioned as the coexistent low platelet count makes it diffi cult in performing and interpreting ex vivo aggregation test in cirrhosis ( 9 ) . Conversely, using more adequate laboratory tests, we demonstrated that platelets from cirrhotic patients are hyperresponsive to common agonists with a mechanism involving upregulation of intracellular signaling implicated in platelet activation ( 10 ) . Low platelet count is another variable that typically occurs in patients with severe liver failure and may predispose to bleeding but its clinical impact is still to be clarifi ed. We have previously reported that bleeding time, which is in part sensitive to platelet count, does not predict bleeding risk in cirrhosis but, because of important infl uence of vessel vasoconstriction on bleeding time, these data were inadequate ( 11 ) . Inconclusive data have also been reported when platelet count was taken into account as a laboratory variable to predict bleeding risk ( 9 ) . Th us, cross-sectional studies provided equivocal data regarding the association between platelet count and spontaneous and provoked bleedings (12) (13) (14) . To the best of our knowledge, there is only one study that prospectively analyzed the impact of platelet count on bleeding risk in cirrhotic patients. Th e study, which included essentially patients with platelet count <150×10 3 /μ l and analyzed only the occurrence of variceal bleeding, demonstrated no relationship between platelet count and bleeding risk ( 15 ) . In order to further explore the role of platelet count on overall bleeding in the "real world" of cirrhotic patients, we prospectively included cirrhotic patients with diff erent degrees of liver disease independently from platelet count. We speculated that if low platelet count actually predisposes to bleeding in cirrhosis, clinical manifestations should not occur exclusively in the gastrointestinal (GI) tract. Th e goal of the study was, therefore, to assess whether platelet count was predictive of GI or non-GI bleeding or both during a follow-up of ∼ 4 years.
METHODS
Th e PRO-LIVER study is an ongoing Italian-based prospective multicenter study with the primary objective to estimate the prevalence of portal vein thrombosis in a cohort of patients with cirrhosis. Th is study was conducted in accordance with the EU Note for Guidance on Good Clinical Practice CPMP/ECH/135/95 and the Declaration of Helsinki. Informed consent was obtained from all individual participants included in the study. Th e study was initiated only aft er local and ethic approval requirements were obtained (ClinicalTrials.gov Identifi er: NCT01470547). Th e Center participation to the registry was voluntary and not sponsored.
Th e study reports a prespecifi ed analysis in a subgroup of the entire PRO-LIVER cohort that aimed at exploring the relationship between platelets count and major or clinical relevant nonmajor bleeding defi ned using the International Society on Th rombosis and Haemostasis (ISTH) criteria.
ISTH major bleeding in nonsurgical patients is defi ned as having a symptomatic presentation as follows ( 16, 17 ) : (i) fatal bleeding, and/or (ii) bleeding in a critical area or organ (intracranial, intraspinal, intraocular, retroperitoneal, intra-articular, pericardial, intramuscular with compartment syndrome), and/or (iii) bleeding causing a fall in hemoglobin level of 20 g/l or more, or leading to transfusion of two or more units of whole blood or red cells.
Any sign or symptom of hemorrhage that (i) required medical intervention by a healthcare professional or (ii) led to hospitalization or increased level of care or (iii) prompted a face-to-face evaluation had been considered a clinical relevant nonmajor bleeding .
Study population
All consecutive cirrhotic out-or in-patients who were referred to the 11 centers participating in the substudy were enrolled. Th e presence of concomitant neoplasms was the only exclusion criteria. Th us, we included patients with a diagnosis of cirrhosis of any etiology and severity. Both Child-Pugh and MELD (Model For End-Stage Liver Disease) scores were assessed to establish the severity of liver disease. Among laboratory variables, prothrombin time-international normalized ratio (PT-INR), total bilirubin, serum albumin, serum creatinine, and platelet counts were mandatory for this substudy.
Data collection and validation have been previously described ( 18 ) . Briefl y, patient identifi cation name was registered in the participating centers, but was not transferred to the central database.
Patients have been identifi ed by a serial number for each center. A fi nal database was created and validated by the study coordinator. A phone call interview was scheduled every 3 months to record all relevant clinical events. A follow-up visit was scheduled every 6 months. At each visit all relevant clinical events, the severity of liver disease, and treatments received during the follow-up period were checked.
Statistical analysis
All continuous variables were tested for normality with the Shapiro-Wilk test. Variables with normal distribution were expressed as mean and s.d., and tested for diff erences with the Student's t-test. Nonnormal variables were expressed as median and interquartile range (IQR) and diff erences tested with the Mann-Whitney U-test. Categorical variables were expressed as counts and percentages and were analyzed by the χ 2 test. Survival curves were formally compared using the log-rank test. Cox proportional hazards analysis was used to calculate the adjusted relative hazards of outcome events by each clinical variable.
Stochastic level of entry into the model was set at a P value=0.10, and interaction terms were explored for all the variables in the fi nal model.
Only P values <0.05 were regarded as statistically signifi cant. All tests were two-tailed and analyses were performed using computer soft ware packages (SPSS-22.0, IBM, Armonk, NY).
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RESULTS
Overall, 280 cirrhotic patients were recruited (188 males; 92 females; age 64±37 years). Viral ( n =122, 44%), alcoholic ( n =79, 28%), and both viral and alcoholic ( n =38, 14%) etiologies were predominant. Compensated cirrhotic patients (Child-Pugh score: A class) were 53 and 47% cirrhotic patients had moderate-severe disease (87 of B and 45 of C class). Mean MELD score was 11±6. Ascites was detected in 120 (43%) patients: 77 (64%) responsive to diuretic therapy and 43 (36%) had a refractory ascites. At the time of enrollment, hepatic encephalopathy (HE) aff ected 62 (22%) patients (53 were in I-II and 9 in III-IV grades). Sixtyfi ve (23%) patients had previous GI bleeding. Compared with the entire cohort, these patients had similar MELD score (11.5±5.4 vs. 11.2±5.7), percentage of moderate-severe disease (52% vs. 45%, P =0.34), ascites (58% vs. 57%), and HE (26% vs. 21%). Moreover, among 19 patients who experienced GI bleeding in the previous 12 months, ∼ 50% had HE at the time of enrollment. Recent esophagogastroduodenoscopy has been reported in 229 out of 280 patients. Among them, 90 (30%) had no esophageal varices. Th e remaining 139 patients had esophageal varices (86 were classifi ed as small (F1), 44 as medium (F2), and 9 as large (F3)) ( 19 ) .
Sixteen patients (6.7%) were on anticoagulants (14 received lowmolecular-weight heparin and 2 vitamin-K antagonist). None of the patients with previous GI bleeding was treated with any kind of anticoagulants.
In all, 145 (52%) patients received aldosterone receptor antagonist, 139 (50%) loop diuretics, and 104 (37%) β -blockers. Th irteen (4.6%) patients were previously treated with endoscopic variceal ligation and 2 with esophageal variceal sclerosis.
Mean serum levels of creatinine and albumin were 0.93±0.47 and 3.39±0.61 g/l, respectively. Median bilirubin was 1.16 (IQR: 0.80-2.0) mg/dl and mean PT-INR was 1.3±0.3 (median (IQR): 1.2 (1.1-1.4)). Platelet counts were 120±63×10 /μ l, P =0.0464). An inverse signifi cant correlation between platelet counts, ChildPugh score (r=−0.13, P =0.030), MELD score (r=−0.17, P =0.006), and PT-INR (r=−0.30, P <0.0001) was also observed; conversely, albumin serum levels signifi cantly correlated with platelet counts (r=0.15, P =0.010).
During the observational period (median length of follow-up was 1,129 (IQR: 800-1,498) days yielding 953.12 patient-years of observation) 52 (18.6%) patients experienced a major or minor bleeding event. Th us, the annual rate of any signifi cant bleeding was 5.45%/year.
Major bleeding events
Th irty-four patients (12%) met the criteria for major events; of them, 31 (91%) experienced a bleeding related to portal hypertension (bleeding episode secondary to the rupture or erosion of esophageal or gastric varices and/or portal hypertensive gastropathy, manifested clinically as melena or hematemesis) that was fatal in 5 patients. At the enrollment, 19 (61%) had gastroesophageal varices (F1=12, F2=4, F3=3): only 8 of them received β -blockers or/and endoscopic variceal ligation/sclerosis. Conversely, seven patients without gastroesophageal varices received prophylaxis with β -blockers.
Th e remaining three included two intracerebral hemorrhage (fatal in one patient) and one from bronchial tree; the median follow-up for the index event was 195 (IQR: 90-553) days. Th us, the annual rate of major bleeding was 3.57%/year. Patients with major bleeding events during the follow-up did not diff er in terms of age, sex, Child-Pugh score, etiology, diuretic therapy, and β -blockers (44% vs. 36%) with those without major bleedings.
MELD score was higher in patients who experienced major bleeding during the follow-up (13.3±5.7 vs. 10.9±5.5, P =0.0215). A higher percentage of previous gastrointestinal bleeding characterized patients with major bleeding during the follow-up (41% vs. 21%, P =0.008).
Patients with major bleeding had more frequently encephalopathy (41% vs. 19.5%, P =0.017); ascites was present in 47% of patients with and in 42% of patients without major bleeding.
Serum albumin, creatinine, and bilirubin median levels were similar between patients with and without major bleeding events. 1 and 2 , model A) . Th e fi nal model of multivariable Cox regression analysis showed that presence of HE (hazard ratio (HR): 2.41; P =0.012) ( Figure 1a ) and previous GI bleeding (HR: 2.29; P =0.018) ( Figure 1b ) independently predicted major bleeding events, aft er adjusting for MELD score and β -blockers treatment. In addition, to ensure that one parameter of MELD score (e.g., INR, creatinine, bilirubin) did not dominate the analysis, the proportional hazards model was run using each component of MELD individually ( Table 2 , model B) . Th e fi nal model confi rmed that HE (HR: 2.47; P =0.010) and previous GI bleeding (HR: 2.40; P =0.012) independently predicted major bleeding events.
Minor bleeding events
Th e median follow-up of 18 patients who had minor bleeding events was 186 (IQR: 30-658) days. Th us, the annual rate of minor bleedings was 1.89%/year. All but one with ecchymosis had bleedings from gastrointestinal tube (upper gastrointestinal system ( n =10), cecum or ascending colon ( n =4), rectal bleeding ( n =3)).
Patient characteristics associated to all bleeding events
Clinical and laboratory characteristics of patients according to the presence of major or nonmajor bleeding are depicted in Table 3 .
No diff erences in age, sex, and etiology were observed between the two groups. Patients with bleedings had more advanced LIVER Platelet Count and Bleeding in Cirrhosis disease, higher percentage of previous gastrointestinal bleeding, and more frequently encephalopathy. Esophageal varices of grade ≥2, ascites, serum albumin, creatinine, and bilirubin median levels did not discriminate the two groups.
Median PT-INR was slightly higher in patients with all types of bleeding. Otherwise, platelet counts did not discriminate patients with and without bleedings. In particular, platelet counts ≤50×10 3 /μ l were detected in 3 (6%) patients with and in 20 (9%) without any bleeding event. Table 4 reported variables univariate analysis and variables that entered the multivariate multivariable Cox regression analysis ( P =0.10) ( Table 5 , model A). Th e fi nal model showed that only previous GI bleeding (HR: 1.96; P =0.020) ( Figure 2a ) and encephalopathy (HR: 2.05; P =0.013) ( Figure 2b ) were signifi cantly associated with bleeding during the follow-up aft er adjusting for serum albumin, β -blocker treatment, and MELD score. Using each component of MELD individually ( Table 5 , model B), the fi nal model Basili et al.
DISCUSSION
Th e results of this prospective study in cirrhotic patients with diff erent degrees of liver failure show that bleeding complication occurs prevalently from gastrointestinal tube and that platelet count is not predictive of overall bleeding risk. In our cohort, the annual rate of overall bleeding was 5.45%/ year, in accordance with previous data mostly considering variceal hemorrhage as a major outcome; in fact, variceal bleeding occurs at a yearly rate between 5 and 15%, depending on cirrhosis severity and variceal size ( 20 ) . Data on other types of bleeding, mainly derived by cross-sectional and retrospective studies, do not permit adequate comparison ( 21 ) .
In our cohort, >90% of major or minor bleedings recognized a gastrointestinal source; major upper GI bleedings from esophageal varices were observed in ∼ 55% of cases. Similar to previous studies (22) (23) (24) , the remaining GI hemorrhagic events recognized a nonvariceal upper GI source or lower GI origin.
Of the remaining bleeding complications, 4 (7.7%) were not from gastrointestinal tube but one cutaneous ecchymosis, one hemoptysis, and two intracerebral hemorrhages, indicating that in cirrhosis bleeding is essentially gastrointestinal. Th us, in accordance with previous reports showing that intracerebral hemorrhage is a very rare complication ( 25, 26 ) , we found this complication in two patients of the entire cohort corresponding to 0.17%/year.
showed that encephalopathy (HR: 2.13; P =0.015), previous GI bleeding (HR: 1.87; P =0.031), and PT-INR (HR: 2.65; P =0.012) independently predicted all bleeding events. (29) Class C, n (%) 12 (24) 33 (15) Child -Pugh score median (IQR)
12 (9-14) 9 (7-12) 0.0193 (14) 37 (21) F3, n (%) 3 (6) 6 ( 15 (29) 58 (25) PT-INR 
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Among the clinical variables considered, previous GI bleeding and encephalopathy were associated with an enhanced risk of overall bleedings. Conversely, global clotting tests such as PT were not predictive of major bleedings, in accordance with the previously reported poor predictive value of clotting tests vs. bleeding risk in cirrhosis ( 3, 27 ) . However, we cannot exclude that other clotting tests may be associated with bleedings as evidenced by previous reports where von Willebrand factor, factor VIII/protein C ratio, and fi brinogen were associated with variceal and nonvariceal bleeding ( 12, 15, 28, 29 ) .
Our fi ndings reinforce and extend the results of a previous study ( 15 ) that demonstrated absence of relationship between platelet count and variceal bleeding in a follow-up of ∼ 3 years. In particular, we observed that platelet count does not predict bleeding events in cirrhotic patients even considering bleeding type and site. Moreover, the entity of thrombocytopenia seemed to have no impact on bleeding events as patients did not display a higher risk of major or minor bleedings even with a low platelet count (≤50×10 3 /μ l). Taken together, these data lead to suggest that, in cirrhosis, platelets maintain a hemostatically adequate function and this is also consistent with the previously reported lack of association between platelet count and bleeding aft er invasive procedures ( 14 ) . It is possible, however, that in particular clinical settings, such as critically ill cirrhotic patients admitted to intensive care units, very low platelet count (<30×10 3 /μ l) is associated with major bleeding in a context of clinical complexity including sepsis and neurologic disorder ( 12 ).
Study limitations
As platelet counts <50×10 3 /μ l were relatively rare (8.2%), this might account for the lack of association between severe thrombocytopenia and bleeding event rate. Furthermore, given the relatively low bleeding rate, we cannot exclude that our sample is underpowered to assess the predictive value of platelet count.
Only 37% of the cohort with esophageal varices were taking β -blockers. Th e increasing controversy about the use of β -blockers in patients with advanced cirrhosis and complications ( 30, 31 ) and the design of this study, which did not require a standardize 
Pathophysiological and clinical implications of the study
Previous studies have suggested that cirrhotic patients suff er not only from thrombocytopenia but also from thrombocytopathy because of impaired platelet response to common agonists ( 9 ) . Our report questions the existence of platelet-related coagulopathy as the bleeding scenario is not compatible with an impaired platelet function. For example, in case of platelet genetic dysfunction and drug-related platelet inhibition, patients suff er from bleeding such as diff use ecchymosis or enhanced risk of cerebral hemorrhage ( 32, 33 ) . Furthermore, no increased bleeding was observed in patients with platelet count ≤50×10 3 /μ l, which is apparently in contrast with the fact that in other hematological disorders this platelet count may be associated with enhanced bleeding risk ( 34 ) . A potential explanation for this fi nding is that platelets from cirrhosis are actually overactivated with a mechanism related to systemic infl ammation and oxidative stress ( 10 ) that could, therefore, protect from bleeding even in the case of low platelet count.
An implication of the study regards the need, if any, to increase platelet count in case of elective or urgent surgery. We have previously questioned the need for the use of eltrombopag in cirrhotic patients with low platelet count as it may expand the number of activated platelets so favoring thrombotic complications ( 35 ) . Th is issue should be seriously considered in the future.
In conclusion, this study shows that in cirrhosis platelet count is not predictive of bleedings, and hence questioning the existence of a thrombocytopathy and suggesting, conversely, that platelet function is adequately preserved.
